Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World

NCT07141914 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07141914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07141914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
August 29, 2025
Completion date
December 19, 2025
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerotic cardiovascular disease (ascvd), heart failure (hf), obesity, overweight, primary prevention